BILLERICA, Mass.--(BUSINESS WIRE)--EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, entered into a collaborative research agreement with Massachusetts General Hospital (MGH) to further the understanding of Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease, where the immune system produces proteins called autoantibodies that attack patients’ own tissues and organs. According to the Lupus Foundation of America, approximately 1.5 million Americans have SLE. Up to 60% of patients with SLE develop inflammation in the kidneys known as Lupus Nephritis (LN), which if uncontrolled can lead to kidney failure. SLE and LN represent an area of high unmet medical need, where new therapies are vital.
Help employers find you! Check out all the jobs and post your resume.
